UA84402C2 - Применение монооксида углерода для лечения воспаления почек - Google Patents

Применение монооксида углерода для лечения воспаления почек

Info

Publication number
UA84402C2
UA84402C2 UA20041210106A UA20041210106A UA84402C2 UA 84402 C2 UA84402 C2 UA 84402C2 UA 20041210106 A UA20041210106 A UA 20041210106A UA 20041210106 A UA20041210106 A UA 20041210106A UA 84402 C2 UA84402 C2 UA 84402C2
Authority
UA
Ukraine
Prior art keywords
carbon monoxide
nephritis
treatment
biomarker
spleen
Prior art date
Application number
UA20041210106A
Other languages
English (en)
Ukrainian (uk)
Inventor
Августин М.К. Чой
Лео Е. Оттербейн
Original Assignee
Йельский Университет
Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йельский Университет, Джонс Хопкинс Юниверсити filed Critical Йельский Университет
Publication of UA84402C2 publication Critical patent/UA84402C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Данное изобретение относится к медицине и касается применения газообразного монооксида углерода для изготовления лекарственного средства при лечении пациента, который страдает от или склонен к риску возникновения локализованного воспаления почек.
UA20041210106A 2002-05-09 2002-05-09 Применение монооксида углерода для лечения воспаления почек UA84402C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Publications (1)

Publication Number Publication Date
UA84402C2 true UA84402C2 (ru) 2008-10-27

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041210106A UA84402C2 (ru) 2002-05-09 2002-05-09 Применение монооксида углерода для лечения воспаления почек

Country Status (13)

Country Link
EP (1) EP1501523A4 (ru)
JP (1) JP2005532314A (ru)
KR (1) KR20040106515A (ru)
CN (1) CN1638781A (ru)
AU (1) AU2002308676B2 (ru)
BR (1) BR0215717A (ru)
CA (1) CA2484770A1 (ru)
EA (1) EA200401478A1 (ru)
MX (1) MXPA04011113A (ru)
NO (1) NO20044865L (ru)
RS (1) RS96904A (ru)
UA (1) UA84402C2 (ru)
WO (1) WO2003094932A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
WO2003066067A2 (en) 2002-02-04 2003-08-14 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
EP1499328B1 (en) 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
MXPA04010243A (es) 2002-04-15 2005-07-05 Univ Pittsburgh Metodos para tratar ileo.
EP1505990B1 (en) * 2002-05-17 2011-08-24 Yale University Methods of treating hepatitis
JP2005345242A (ja) * 2004-06-02 2005-12-15 Tohoku Univ 肺癌の化学療法治療効果の評価方法
WO2007073005A1 (ja) * 2005-12-22 2007-06-28 Keio University メチル基転移反応調節物質
WO2008069688A2 (en) * 2006-12-06 2008-06-12 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
BR112013017933B1 (pt) * 2011-01-14 2021-02-23 Children's Hospital Los Angeles composição líquida e métodos para sua fabricação
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9359197B2 (en) 2011-03-24 2016-06-07 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring parkinson's disease
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
US10031126B2 (en) 2013-04-04 2018-07-24 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
JP7161737B2 (ja) * 2017-01-30 2022-10-27 哲也 石川 悪性腫瘍の検査方法
JP7396597B2 (ja) 2018-06-08 2023-12-12 住友精化株式会社 炎症性消化器官疾患用組成物
US20210228621A1 (en) * 2018-06-08 2021-07-29 Sumitomo Seika Chemicals Co., Ltd. Composition for skin wounds
WO2020247825A1 (en) * 2019-06-06 2020-12-10 The General Hospital Corporation Carbon monoxide as a treatment for neurodegenerative disease
US20230346831A1 (en) * 2020-07-16 2023-11-02 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
ES2210585T3 (es) * 1996-08-27 2004-07-01 Messer Griesheim Gmbh Medicamento que contiene hidrogeno.
MXPA03008820A (es) * 2001-03-30 2004-07-30 Sangstat Medical Corp Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.

Also Published As

Publication number Publication date
KR20040106515A (ko) 2004-12-17
WO2003094932A1 (en) 2003-11-20
CN1638781A (zh) 2005-07-13
AU2002308676A1 (en) 2003-11-11
BR0215717A (pt) 2005-02-22
CA2484770A1 (en) 2003-11-20
AU2002308676B2 (en) 2009-06-11
EP1501523A1 (en) 2005-02-02
NO20044865L (no) 2004-12-07
JP2005532314A (ja) 2005-10-27
EP1501523A4 (en) 2006-12-13
MXPA04011113A (es) 2005-02-14
RS96904A (en) 2007-02-05
EA200401478A1 (ru) 2005-12-29

Similar Documents

Publication Publication Date Title
UA84402C2 (ru) Применение монооксида углерода для лечения воспаления почек
EP2228654A3 (en) Diagnosis and prevention of cancer cell invasion
WO2004078124A3 (en) Methods and compositions involving mda-7
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
EP1571968A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
PL1656346T3 (pl) 1,2,3,4-Tetrapodstawiony indol do leczenia chorób dróg oddechowych
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
EP1572091A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
EP1553912A4 (en) COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
EP1578996A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
MX2007013834A (es) Terapias de enfermedades vasculares.
EP1575571A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
WO2007014943A3 (en) Therapy for neurological diseases
HK1121083A1 (en) Methods for reducing blood pressure
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
NZ546440A (en) Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
HK1106246A1 (en) S-tenatoprazole monohydrated sodium salt and the use thereof in therapy s-